Biotechnology & Pharmaceuticals

Home / Industries / Biotechnology & Pharmaceuticals

Trevisan & Cuonzo’s biotechnology and pharmaceutical team is a jewel in the crown of its globally renowned IP practice.

The outstanding achievements of our team in the last twenty years has gained us a client portfolio in the pharma and biotech sectors that is second to none in Italy, and among the most significant in Europe.

Both the regulatory and the litigation teams are the “must-go-to” practices in Italy for the more challenging pharma and biotech cases.

Recent notable cases:

  • Assisting a global biopharmaceutical group in defending its patent rights concerning an innovative anticancer drug of crucial importance for the treatment of certain neoplasms
  • Assisting a renowned Italian biopharmaceutical company and its licensee in the prosecution and enforcement of patents and related SPCs for use in treating the Parkinson’s disease
  • Representing one of the world's largest pharmaceutical companies in patent infringement proceedings brought against an API manufacturer. The decision established a new principle of law on the interpretation of the Bolar clause under Italian law
  • Assisting a pharmaceutical giant before the UPC Milan Central Division in a patent litigation concerning the infringement of a second medical use patent covering a specific form of administration of an active ingredient
  • Representing a top-5 multinational pharmaceutical company in a dispute concerning the enforcement of patents protecting a blockbuster medicinal product for the treatment of diabetes
  • Representing one of the most important biopharmaceutical multinationals in relation to a dispute concerning patent protection for the second medical use of an anticancer drug for the treatment of breast cancer
  • Assisting a Japanese multinational pharmaceutical company in the framework of patent invalidity proceedings, instigated before the Court of Milan by a Dutch pharmaceutical company, in relation to a key medicinal product for the treatment of prostate cancer
  • Assisting a Swiss pharmaceutical company in negotiations with the Italian Regulatory Authority concerning the pay-back procedure
  • Defending a global pharmaceutical company in litigation concerning the effects of orphan drug designation and its interaction with SPC protection, in relation to a blockbuster anti-cancer drug

Experienced in representing clients from the pharmaceutical and biotechnology sectors before Italian courts.

Chambers Europe, 2025